Immuneering Corp Quarterly Operating Income (Loss) in USD from Q2 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Immuneering Corp quarterly/annual Operating Income (Loss) history and growth rate from Q2 2020 to Q3 2024.
  • Immuneering Corp Operating Income (Loss) for the quarter ending September 30, 2024 was -$15.3M, a 9.68% decline year-over-year.
  • Immuneering Corp Operating Income (Loss) for the twelve months ending September 30, 2024 was -$61.8M, a 10.2% decline year-over-year.
  • Immuneering Corp annual Operating Income (Loss) for 2023 was -$58.4M, a 12.9% decline from 2022.
  • Immuneering Corp annual Operating Income (Loss) for 2022 was -$51.7M, a 52.7% decline from 2021.
  • Immuneering Corp annual Operating Income (Loss) for 2021 was -$33.9M, a 98.4% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$61.8M -$15.3M -$1.35M -9.68% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 -$60.5M -$14.9M -$1.41M -10.4% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 -$59.1M -$15.3M -$646K -4.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 -$58.4M -$16.3M -$2.32M -16.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-01
Q3 2023 -$56.1M -$13.9M -$738K -5.6% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$55.4M -$13.5M -$1.86M -16% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 -$53.5M -$14.7M -$1.75M -13.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 -$51.7M -$14M -$2.87M -25.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-01
Q3 2022 -$48.9M -$13.2M -$4.64M -54.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$44.2M -$11.6M -$3.66M -45.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 -$40.6M -$12.9M -$6.69M -107% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$33.9M -$11.1M Oct 1, 2021 Dec 31, 2021 10-K 2023-03-06
Q3 2021 -$8.54M -$4.14M -94.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$7.99M -$4.38M -122% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-10
Q1 2021 -$6.24M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q3 2020 -$4.4M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 -$3.61M Apr 1, 2020 Jun 30, 2020 10-Q 2021-09-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.